AI Drug Discovery Gets Smarter with Better Data Systems

Developing a new drug takes up to 15 years and costs $2.5 billion, with nine out of ten candidates failing before they reach patients. But artificial intelligence is changing those odds by helping scientists design better drug candidates in a fraction of the time.

Paul Belcher, director of protein research strategy at global life sciences company Cytiva, has watched AI transform how drug companies discover new treatments. Instead of physically testing hundreds of thousands of compounds to find one that works, scientists now use AI to design drug candidates from scratch and predict how they'll interact with disease targets.

"AI does away with that," says Belcher. "And it can help eliminate low-quality candidates before you have to physically test them, saving time and resources."

The shift is creating waves of progress. Drug companies are no longer limited by how much they can physically screen in a lab. They're getting more hits, better quality hits, and potentially life-saving treatments to patients years faster.

But AI revealed a critical problem: the models were only as good as the data feeding them. Many early AI systems trained on publicly available datasets that focused exclusively on successful experiments, missing the crucial lessons hidden in failures.

"No one wants to share their failures," Belcher explains. "This bias is almost like having one hand tied behind your back."

To solve this, companies like Cytiva are developing tools that ensure data integrity and completeness. Their Image Integrity Checker uses the same technology as blockchain to verify that lab images haven't been manipulated, addressing a problem that affects nearly 4% of biomedical research papers.

The advances are helping labs handle the growing volume of AI-generated candidates that need validation. Scientists now have access to higher-throughput, information-rich technologies that can characterize promising compounds in detail, not just give yes-or-no answers.

The Ripple Effect

This isn't just about faster drug development. Every percentage point improvement in success rates could mean breakthrough treatments reaching patients years earlier. When clinical trials represent the biggest cost in drug discovery, better AI candidates mean fewer expensive failures and more resources directed toward treatments that actually work.

The combination of smarter AI and better data systems is helping reverse Eroom's Law, the decades-long trend of drug development costs doubling every nine years. As more companies adopt these data integrity tools and share comprehensive datasets, the entire pharmaceutical industry benefits from more reliable predictions.

The breakthrough treatments of tomorrow are being designed today, with AI and human scientists working together better than ever before.